Last reviewed · How we verify
Detox-B adjuvant
Detox-B adjuvant is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Vaccine adjuvant (indication under investigation in phase 3).
Detox-B adjuvant enhances immune response by promoting detoxification pathways and supporting innate immunity.
Detox-B adjuvant enhances immune response by promoting detoxification pathways and supporting innate immunity. Used for Vaccine adjuvant (indication under investigation in phase 3).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable. -
Big-pharma sponsor
+3.0pp
GlaxoSmithKline is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Detox-B adjuvant |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As an adjuvant, Detox-B is designed to augment the body's natural detoxification mechanisms while simultaneously boosting immune activation. The exact molecular pathways remain proprietary, but adjuvants of this class typically work by activating pattern recognition receptors or enhancing antigen presentation to strengthen vaccine or immunotherapy efficacy.
Approved indications
- Vaccine adjuvant (indication under investigation in phase 3)
Common side effects
Key clinical trials
- Social Media Diet and Psychological Outcomes in University Students (NA)
- Reducing Digital Distractions to Improve Time Management Among Nursing Students (NA)
- Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection (PHASE1)
- ADHD: Gaps Between Patients With Alcohol-dependence and Impact on Relapse
- Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition (NA)
- Digital Silence and Mental Health (NA)
- Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention (PHASE2)
- The Effect of Art-Based Nursing Intervention Helping to Develop Healthy Digital Habits on Digital Addiction, Cyberbullying and Self-Efficacy in Adolescents (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Detox-B adjuvant CI brief — competitive landscape report
- Detox-B adjuvant updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Detox-B adjuvant
What is Detox-B adjuvant?
How does Detox-B adjuvant work?
What is Detox-B adjuvant used for?
Who makes Detox-B adjuvant?
What development phase is Detox-B adjuvant in?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Vaccine adjuvant (indication under investigation in phase 3)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing